RecruitingKidney Transplant Recipients
The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients
Eligible age
18+ yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The study aims to determine the short-term efficacy, mechanisms and safety of 12 weeks of dapagliflozin and semaglutide combination therapy in 20 KTR, with and without T2D.
Sponsor: University Health Network, Toronto
You may qualify if…
- ✓ Signed and dated written informed consent.
- ✓ Patients aged ≥18 years with KTR
- ✓ \>3 months post kidney transplantation
- ✓ Estimated glomerular filtration rate \[eGFR\] ≥20 ml/min/1.73m2
- ✓ BP \<160/100 and \>90/60 at screening
- ✓ Body-mass index \[BMI\] between 18.5-40kg/m2
- ✓ In patients with T2D or PTDM, HbA1c \<12.0%;
You may not qualify if…
- ✕ Type 1 diabetes.
- ✕ History of multi-organ transplant
- ✕ Acute coronary syndrome, transient ischemic attack or stroke within 30 days prior to screening
- ✕ Impending need for kidney biopsy or rapid decline in eGFR within 30 days prior to screening
- ✕ Actively treated BK, CMV or EBV infection
- ✕ Recurrent pyelonephritis or need for indwelling or self-catheterization
- ✕ Prior amputation or ischemic rest pain
- ✕ Women who are pregnant, nursing, or who plan to become pregnant whilst in the trial.
Source: ClinicalTrials.gov · NCT05938712 · last updated 2026-05-01